http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
-
Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
-
Ionis Pharmaceuticals (IONS) Announces Brett P. Monia Ph.D. to Board
-
Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
-
Akcea Therapeutics (AKCA), Ionis (IONS) Announce Upcoming Data Presentations at ACC.19
-
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
-
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Ionis Pharmaceuticals Inc. (IONS), Akcea Therapeutics (AKCA) Report Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
-
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
-
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
-
Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
-
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
-
Ionis Exceeds 2018 Financial Guidance
-
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
-
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
-
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast
-
Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast
-
Ionis Pharmaceuticals (IONS) Reports First Patient Enrollment in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
-
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
-
Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
-
Ionis Announces Plans for Management Transitions in 2020
-
Biogen (BIIB) Exercises Option with Ionis (IONS) to Develop, Commercialize Investigational Treatment BIIB067 for Subtype of Familial ALS Based on Positive Phase 1 Data
-
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
-
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
-
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
-
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
-
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
-
Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference
-
Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Highlight Phase 2 Results on AKCEA-APO(a)-LRx in Late-Breaking Clinical Trial Presentation
-
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
-
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
-
Ionis Pharmaceuticals to Host Investor Day
-
Akcea Therapeutics (AKCA), Ionis (IONS) Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at AHA
-
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
-
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Ionis Reports Third Quarter 2018 Financial Results
-
Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
-
Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast
-
Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science
-
Ionis Pharmaceuticals (IONS) Reports New Phase 1b/2 Trial Data on Danvatirsen (formerly IONIS-STAT3-2.5Rx, aka AZD9150) at ESMO 2018
-
Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology
-
Ionis Pharmaceuticals (IONS) Enters Pact with Roche to Develop IONIS-FB-L Rx for Complement-Mediated
-
Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
-
Akcea (AKCA), Ionis (IONS) Receive FDA Approval of TEGSEDI (Earlier)
-
Biogen (BIIB) Reports New Interim Study Results from NURTURE
-
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

